Skip to main content
Top
Published in: Supportive Care in Cancer 3/2021

01-03-2021 | Prostate Cancer | Original Article

Strategies for living well with hormone-responsive advanced prostate cancer—a qualitative exploration

Authors: Lauren Matheson, Jo Nayoan, Carol Rivas, Jo Brett, Penny Wright, Hugh Butcher, Paul Jordan, Anna Gavin, Adam Glaser, Malcolm Mason, Richard Wagland, Eila Watson

Published in: Supportive Care in Cancer | Issue 3/2021

Login to get access

Abstract

Purpose

Due to recent treatment advances, men are increasingly living longer with advanced prostate cancer (PCa). This study sought to understand men’s experiences of living with and adjusting to advanced hormone-responsive PCa and how this influenced their quality of life (QoL), in order to highlight how support could be optimized.

Methods

Participants were recruited through a UK wide survey—the ‘Life After Prostate Cancer Diagnosis’ study. In-depth telephone interviews were conducted with 24 men (aged 46–77 years) with advanced (stage IV) hormone-responsive PCa diagnosed 18–42 months previously. Thematic analysis was undertaken using a framework approach.

Results

Most participants perceived their QoL to be relatively good, which was influenced by the following factors (enablers to ‘living well’ with PCa): a sense of connectedness to others, engagement in meaningful activities, resources (social, cognitive, financial), ability to manage uncertainty, utilization of adjustment strategies and support, communication and information from health professionals. Barriers to ‘living well’ with PCa were often the converse of these factors. These also included more troublesome PCa-related symptoms and stronger perceptions of loss and restriction.

Conclusions

In our study, men living with advanced hormone-responsive PCa often reported a good QoL. Exploring the influences on QoL in men with advanced PCa indicates how future interventions might improve the QoL of men who are struggling. Further research is required to develop and test interventions that enhance QoL for these men.
Appendix
Available only for authorised users
Literature
4.
go back to reference James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O’Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. NEJM 377(4):338–351. https://doi.org/10.1056/NEJMoa1702900CrossRefPubMed James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O’Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. NEJM 377(4):338–351. https://​doi.​org/​10.​1056/​NEJMoa1702900CrossRefPubMed
5.
go back to reference Watson E, Shinkins B, Frith E, Neal D, Hamdy F, Walter F, Weller D, Wilkinson C, Faithfull S, Wolstenholme J, Sooriakumaran P, Kastner C, Campbell C, Neal R, Butcher H, Matthews M, Perera R, Rose P (2016) Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up. BJU Int 117(6B):E10–E19. https://doi.org/10.1111/bju.13122CrossRefPubMed Watson E, Shinkins B, Frith E, Neal D, Hamdy F, Walter F, Weller D, Wilkinson C, Faithfull S, Wolstenholme J, Sooriakumaran P, Kastner C, Campbell C, Neal R, Butcher H, Matthews M, Perera R, Rose P (2016) Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up. BJU Int 117(6B):E10–E19. https://​doi.​org/​10.​1111/​bju.​13122CrossRefPubMed
9.
12.
14.
go back to reference Rivas C, Matheson L, Nayoan J, Glaser A, Gavin A, Watson E, Wagland R (Submitted) Men’s transformations following a prostate cancer diagnosis and opportunities for intervention: a metaethnographic study Rivas C, Matheson L, Nayoan J, Glaser A, Gavin A, Watson E, Wagland R (Submitted) Men’s transformations following a prostate cancer diagnosis and opportunities for intervention: a metaethnographic study
22.
go back to reference Downing A, Wright P, Wagland R, Watson E, Kearney T, Mottram R, Allen M, Cairnduff V, McSorley O, Butcher H, Hounsome L, Donnelly C, Selby P, Kind P, Cross W, Catto JW, Huws D, Brewster DH, McNair E, Matheson L, Rivas C, Nayoan J, Horton M, Corner J, Verne J, Gavin A, Glaser AW (2016) Life after prostate cancer diagnosis: protocol for a UK-wide patient-reported outcomes study. BMJ Open 6(12):e013555. https://doi.org/10.1136/bmjopen-2016-013555CrossRefPubMedPubMedCentral Downing A, Wright P, Wagland R, Watson E, Kearney T, Mottram R, Allen M, Cairnduff V, McSorley O, Butcher H, Hounsome L, Donnelly C, Selby P, Kind P, Cross W, Catto JW, Huws D, Brewster DH, McNair E, Matheson L, Rivas C, Nayoan J, Horton M, Corner J, Verne J, Gavin A, Glaser AW (2016) Life after prostate cancer diagnosis: protocol for a UK-wide patient-reported outcomes study. BMJ Open 6(12):e013555. https://​doi.​org/​10.​1136/​bmjopen-2016-013555CrossRefPubMedPubMedCentral
24.
go back to reference Matheson L, Watson EK, Nayoan J, Wagland R, Glaser A, Gavin A, Wright P, Rivas C (2017) A qualitative metasynthesis exploring the impact of prostate cancer and its management on younger, unpartnered and gay men. Eur J Cancer Care 26(6). https://doi.org/10.1111/ecc.12676 Matheson L, Watson EK, Nayoan J, Wagland R, Glaser A, Gavin A, Wright P, Rivas C (2017) A qualitative metasynthesis exploring the impact of prostate cancer and its management on younger, unpartnered and gay men. Eur J Cancer Care 26(6). https://​doi.​org/​10.​1111/​ecc.​12676
26.
go back to reference QSR International Pty Ltd (2016) NVivo qualitative data analysis Software: version 11 QSR International Pty Ltd (2016) NVivo qualitative data analysis Software: version 11
30.
go back to reference Wright P, Wilding S, Watson E, Downing A, Selby P, Hounsome L, Wagland R, Brewster DH, Huws D, Butcher H, Mottram R, Kearney T, Allen M, Gavin A, Glaser A (2019) Key factors associated with social distress after prostate cancer: results from the United Kingdom Life after Prostate Cancer diagnosis study. Cancer Epidemiol 60:201–207. https://doi.org/10.1016/j.canep.2019.04.006CrossRefPubMed Wright P, Wilding S, Watson E, Downing A, Selby P, Hounsome L, Wagland R, Brewster DH, Huws D, Butcher H, Mottram R, Kearney T, Allen M, Gavin A, Glaser A (2019) Key factors associated with social distress after prostate cancer: results from the United Kingdom Life after Prostate Cancer diagnosis study. Cancer Epidemiol 60:201–207. https://​doi.​org/​10.​1016/​j.​canep.​2019.​04.​006CrossRefPubMed
33.
go back to reference Wilding S, Downing A, Wright P, Selby P, Watson E, Wagland R, Donnelly D, Mason M, Henry A, Gavin A, Glaser AW (In preparation) Cancer-related symptoms, mental well-being and psychological distress in men diagnosed with prostate cancer treated with androgen deprivation therapy Wilding S, Downing A, Wright P, Selby P, Watson E, Wagland R, Donnelly D, Mason M, Henry A, Gavin A, Glaser AW (In preparation) Cancer-related symptoms, mental well-being and psychological distress in men diagnosed with prostate cancer treated with androgen deprivation therapy
34.
go back to reference Downing A, Wright P, Hounsome L, Selby P, Wilding S, Watson E, Wagland R, Kind P, Donnelly D, Butcher H (2018) Quality of life in men living with advanced and localised prostate cancer: a United Kingdom population-wide patient-reported outcome study of 30,000 men. Lancet Oncol Downing A, Wright P, Hounsome L, Selby P, Wilding S, Watson E, Wagland R, Kind P, Donnelly D, Butcher H (2018) Quality of life in men living with advanced and localised prostate cancer: a United Kingdom population-wide patient-reported outcome study of 30,000 men. Lancet Oncol
35.
go back to reference Antonovsky A (1979) Health, stress and coping. Jossey-Bass, San Fransisco Antonovsky A (1979) Health, stress and coping. Jossey-Bass, San Fransisco
37.
go back to reference Antonovsky A (1987) Unraveling the mystery of health. How people manage stress and stay well. Jossey-Bass, San Fransisco, London Antonovsky A (1987) Unraveling the mystery of health. How people manage stress and stay well. Jossey-Bass, San Fransisco, London
38.
go back to reference Mishel MH (1990) Reconceptualization of the uncertainty in illness theory. Image J Nurs Sch 22(4):256–262CrossRefPubMed Mishel MH (1990) Reconceptualization of the uncertainty in illness theory. Image J Nurs Sch 22(4):256–262CrossRefPubMed
43.
go back to reference Courtenay WH (2000) Constructions of masculinity and their influence on men's well-being: a theory of gender and health. Soc Sci Med 50(10):1385–1401CrossRefPubMed Courtenay WH (2000) Constructions of masculinity and their influence on men's well-being: a theory of gender and health. Soc Sci Med 50(10):1385–1401CrossRefPubMed
Metadata
Title
Strategies for living well with hormone-responsive advanced prostate cancer—a qualitative exploration
Authors
Lauren Matheson
Jo Nayoan
Carol Rivas
Jo Brett
Penny Wright
Hugh Butcher
Paul Jordan
Anna Gavin
Adam Glaser
Malcolm Mason
Richard Wagland
Eila Watson
Publication date
01-03-2021
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 3/2021
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-020-05594-8

Other articles of this Issue 3/2021

Supportive Care in Cancer 3/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine